Prediction of the therapeutic dose for β-stimulants based on preclinical data: Application of oral dosage forms and aerosols to asthmatic patients

Kiyomi Ito, Naoko Yajima, Hisakazu Ohtani, Yasuhiko Yamada, Kouichi Nakamura, Yasufumi Sawada, Tatsuji Iga

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The therapeutic doses of β-stimulants in the treatment of bronchial asthma show wide variation among the drugs. In the present study, we tried to construct a system for prediction of the optimum clinical dose of β-stimulants as oral dosage forms and aerosols using the data from preclinical pharmacological studies and pharmacokinetic data in humans. Values of EC50 (drug concentration that gives the half-maximum bronchodilator effect) in the in vitro studies based on isolated trachea of guinea pigs were collected from the literature. The ratios of the EC50 value of each drug to that of isoproterenol were used as the indicator of in vitro pharmacological activity. There were significant correlations between the EC50 ratios and the oral dose or the maximum plasma concentration after single oral administration, but the correlation coefficients were relatively small (r<.9). On the other hand, a linear log-log relationship was observed between the EC50 ratio and the maximum plasma unbound concentration (Cumax) (slope=0.907, r=.955, p<0.001). In the case of aerosols, a good correlation was observed between the EC50 ratio and the dose (slope=0.770, r=.900, p<0.01). The predicted concentration of β-stimulants in the lung after aerosol administration tended to be higher than the Cumax after oral administration, suggesting the contribution of nonspecific binding in the lung tissue. These findings indicate the possibility of predicting the appropriate dose of β-stimulants based on the preclinical pharmacological data and the pharmacokinetic data in humans.

Original languageEnglish
Pages (from-to)133-144
Number of pages12
JournalJournal of Pharmacokinetics and Biopharmaceutics
Volume21
Issue number2
DOIs
Publication statusPublished - 1993 Apr
Externally publishedYes

Fingerprint

Dosage Forms
Aerosols
Pharmacology
Oral Administration
Pharmacokinetics
Pharmaceutical Preparations
Lung
Bronchodilator Agents
Trachea
Isoproterenol
Guinea Pigs
Therapeutics
Asthma
In Vitro Techniques

Keywords

  • β-agonists
  • β-stimulant
  • bronchial asthma
  • dosing rate prediction
  • therapeutic dose

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Prediction of the therapeutic dose for β-stimulants based on preclinical data : Application of oral dosage forms and aerosols to asthmatic patients. / Ito, Kiyomi; Yajima, Naoko; Ohtani, Hisakazu; Yamada, Yasuhiko; Nakamura, Kouichi; Sawada, Yasufumi; Iga, Tatsuji.

In: Journal of Pharmacokinetics and Biopharmaceutics, Vol. 21, No. 2, 04.1993, p. 133-144.

Research output: Contribution to journalArticle

Ito, Kiyomi ; Yajima, Naoko ; Ohtani, Hisakazu ; Yamada, Yasuhiko ; Nakamura, Kouichi ; Sawada, Yasufumi ; Iga, Tatsuji. / Prediction of the therapeutic dose for β-stimulants based on preclinical data : Application of oral dosage forms and aerosols to asthmatic patients. In: Journal of Pharmacokinetics and Biopharmaceutics. 1993 ; Vol. 21, No. 2. pp. 133-144.
@article{902b06374e0844b7a19d903544667fe1,
title = "Prediction of the therapeutic dose for β-stimulants based on preclinical data: Application of oral dosage forms and aerosols to asthmatic patients",
abstract = "The therapeutic doses of β-stimulants in the treatment of bronchial asthma show wide variation among the drugs. In the present study, we tried to construct a system for prediction of the optimum clinical dose of β-stimulants as oral dosage forms and aerosols using the data from preclinical pharmacological studies and pharmacokinetic data in humans. Values of EC50 (drug concentration that gives the half-maximum bronchodilator effect) in the in vitro studies based on isolated trachea of guinea pigs were collected from the literature. The ratios of the EC50 value of each drug to that of isoproterenol were used as the indicator of in vitro pharmacological activity. There were significant correlations between the EC50 ratios and the oral dose or the maximum plasma concentration after single oral administration, but the correlation coefficients were relatively small (r<.9). On the other hand, a linear log-log relationship was observed between the EC50 ratio and the maximum plasma unbound concentration (Cumax) (slope=0.907, r=.955, p<0.001). In the case of aerosols, a good correlation was observed between the EC50 ratio and the dose (slope=0.770, r=.900, p<0.01). The predicted concentration of β-stimulants in the lung after aerosol administration tended to be higher than the Cumax after oral administration, suggesting the contribution of nonspecific binding in the lung tissue. These findings indicate the possibility of predicting the appropriate dose of β-stimulants based on the preclinical pharmacological data and the pharmacokinetic data in humans.",
keywords = "β-agonists, β-stimulant, bronchial asthma, dosing rate prediction, therapeutic dose",
author = "Kiyomi Ito and Naoko Yajima and Hisakazu Ohtani and Yasuhiko Yamada and Kouichi Nakamura and Yasufumi Sawada and Tatsuji Iga",
year = "1993",
month = "4",
doi = "10.1007/BF01059766",
language = "English",
volume = "21",
pages = "133--144",
journal = "Journal of Pharmacokinetics and Pharmacodynamics",
issn = "1567-567X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Prediction of the therapeutic dose for β-stimulants based on preclinical data

T2 - Application of oral dosage forms and aerosols to asthmatic patients

AU - Ito, Kiyomi

AU - Yajima, Naoko

AU - Ohtani, Hisakazu

AU - Yamada, Yasuhiko

AU - Nakamura, Kouichi

AU - Sawada, Yasufumi

AU - Iga, Tatsuji

PY - 1993/4

Y1 - 1993/4

N2 - The therapeutic doses of β-stimulants in the treatment of bronchial asthma show wide variation among the drugs. In the present study, we tried to construct a system for prediction of the optimum clinical dose of β-stimulants as oral dosage forms and aerosols using the data from preclinical pharmacological studies and pharmacokinetic data in humans. Values of EC50 (drug concentration that gives the half-maximum bronchodilator effect) in the in vitro studies based on isolated trachea of guinea pigs were collected from the literature. The ratios of the EC50 value of each drug to that of isoproterenol were used as the indicator of in vitro pharmacological activity. There were significant correlations between the EC50 ratios and the oral dose or the maximum plasma concentration after single oral administration, but the correlation coefficients were relatively small (r<.9). On the other hand, a linear log-log relationship was observed between the EC50 ratio and the maximum plasma unbound concentration (Cumax) (slope=0.907, r=.955, p<0.001). In the case of aerosols, a good correlation was observed between the EC50 ratio and the dose (slope=0.770, r=.900, p<0.01). The predicted concentration of β-stimulants in the lung after aerosol administration tended to be higher than the Cumax after oral administration, suggesting the contribution of nonspecific binding in the lung tissue. These findings indicate the possibility of predicting the appropriate dose of β-stimulants based on the preclinical pharmacological data and the pharmacokinetic data in humans.

AB - The therapeutic doses of β-stimulants in the treatment of bronchial asthma show wide variation among the drugs. In the present study, we tried to construct a system for prediction of the optimum clinical dose of β-stimulants as oral dosage forms and aerosols using the data from preclinical pharmacological studies and pharmacokinetic data in humans. Values of EC50 (drug concentration that gives the half-maximum bronchodilator effect) in the in vitro studies based on isolated trachea of guinea pigs were collected from the literature. The ratios of the EC50 value of each drug to that of isoproterenol were used as the indicator of in vitro pharmacological activity. There were significant correlations between the EC50 ratios and the oral dose or the maximum plasma concentration after single oral administration, but the correlation coefficients were relatively small (r<.9). On the other hand, a linear log-log relationship was observed between the EC50 ratio and the maximum plasma unbound concentration (Cumax) (slope=0.907, r=.955, p<0.001). In the case of aerosols, a good correlation was observed between the EC50 ratio and the dose (slope=0.770, r=.900, p<0.01). The predicted concentration of β-stimulants in the lung after aerosol administration tended to be higher than the Cumax after oral administration, suggesting the contribution of nonspecific binding in the lung tissue. These findings indicate the possibility of predicting the appropriate dose of β-stimulants based on the preclinical pharmacological data and the pharmacokinetic data in humans.

KW - β-agonists

KW - β-stimulant

KW - bronchial asthma

KW - dosing rate prediction

KW - therapeutic dose

UR - http://www.scopus.com/inward/record.url?scp=0027437841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027437841&partnerID=8YFLogxK

U2 - 10.1007/BF01059766

DO - 10.1007/BF01059766

M3 - Article

C2 - 7901385

AN - SCOPUS:0027437841

VL - 21

SP - 133

EP - 144

JO - Journal of Pharmacokinetics and Pharmacodynamics

JF - Journal of Pharmacokinetics and Pharmacodynamics

SN - 1567-567X

IS - 2

ER -